Hasting's prior Co. Incyte, page-3

Id like to think the parrallels with incyte is not so much Hastings but the fact Incyte was itself on the precipice but managed to get financing despite them chewing up a billion dollars in retained losses (nearly $2 billion today) at the time. And on a risk basis, incyte was probably a bigger risk given their products were a 50-50 proposition. Of course biotech companies attract higher premiums than medtechs but but if people believe we have good products then we should attract financing despite our history. Anyhoo, thats the theory. As for Hastings, the Virgin Islands Con Note deflated my opinion of him...